The VANHEALTHING Cryptofund of Biotech innovations is an absolutely unique investment platform: profits are combined with premier access to cutting-edge biotechnological projects that save and improve human lives.

ICO starts in

*This field is required

team: managers

Alexander Lobanov

Managing partner and board member of USP Capital Ltd. and VANHEALTHING Cryptofund of biotech innovations.

team: managers

Alexander Tulko

Managing partner and board member of venture capital fund USP Capital Ltd. And VANHEALTHING Cryptofund of biotech innovations.

team: managers

Yaroslav Kologryvov

Managing partner of VANHEALTHING Cryptofund of biotech innovations. Expert in investment and high-tech ecosystems.

team: scientists

Eugene Nayshtetik

CEO and co-founder of biotech company Planexta Inc. Expert in biotech management.

team: scientists

Valeriy Kanevskiy

PhD in biophysics, director of the Institute of High Technologies. Leads projects in bio-photonics, oncology, medical lasers and other fields.

team: scientists

Yuriy Timoshenko

PhD in technical sciences, expert in complex mathematical analysis. Author of advanced computational models in biotech projects (for example – reading a person’s biodata and emotional state through a phone camera).

team: scientists

Timur Shemsedinov

World-class Big Data and computer engineering researcher. Author of Metarhia – a cutting-edge Big Data analytics engine used by Chinese interactive TV channels.

team: managers

Inna Malyukova

Founder and managing Partner of Sikorsky Challenge

team: scientists

Tetiana Botsva

Head of R&D and co-founder of Planexta, Inc. Expert in medical research and tech implementation.

team: scientists

Sergey Stirenko

Sergey Stirenko is the head of the R&D department of supercomputer calculations, AI and AR/VR of the VANHEALTHING Cryptofund of biotech innovations. Sergey is a high-level specialist in the field of artificial intelligence, virtual and augmented reality, as well as supercomputer calculations.


Improve your life and shape the future!


We provide amazing biotech products that normally take years to reach the public. Don’t wait to increase your life’s span and quality – get access now!


Medical technologies should be affordable and transparent. We believe in a sustainable business model based on social responsibility and earning our clients’ trust.


Invest efficiently into functioning successful projects and early R&D advancements. We offer complete transparency, great profit projections and effective financial management.


Read about us in full detail! VANHEALTHING opens up an entire world of astounding biotechnological projects. We present a comprehensive description of our successful portfolio companies, world-class scientists, professional managers and investment methods.


September 2014

First angel investment into the Force project.

June 2015

The USP Capital venture fund is launched.

September 2015

First successful Kickstarter campaign completed by our portfolio company.

November 2015

Successful cardio-screening of 22 433 patients in rural areas. The Platform 20k project is born.

December 2015

Plans for the world’s first psychometer are formulated – a unique device for constant monitoring of an individual’s psycho-emotional state.

January 2016

The TRL3 experiment for the world’s first one-hand ECG sensor is successfully conducted.

February 2016

Incorporation of Platform 20k and Planexta Inc.

April 2016

Start of development on PRECISE – the automated ECG interpretation project.

September 2016

Start of development on the world’s first sleeveless arterial blood pressure monitor with +-5 mm Hg accuracy.

October 2016

Creation of the SenceBand TRL6 prototype.

November 2016

Successful completion of the SenceBand crowdfunding campaign.

January 2016

SenceBand receives two CES 2017 awards in the biotechnologies and wearable devices categories.

March 2017

  • One of our portfolio companies is chosen for the Vertical accelerator (Finland), considered to be one of the world’s best accelerators in digital health tech.

The TRL4 prototype is created by Planexta Care. This is the world’s first sleeveless arterial blood pressure monitor with +-3 mm Hg accuracy.

April 2017

  • One of our portfolio companies is chosen for the Alchemist accelerator (U.S.A.), considered to be one of the world’s best accelerator programs.
  • The digital beta of PRECISE is launched.

May 2017

Start of clinical trials for PRECISE.

July 2017

The Fund’s portfolio increases to 12 companies – a major new milestone.

August 2017

Start of the Fund’s transformation into a cryptocurrency fund.

  • Creation of the TRL4 prototype of Pure Purr – a VR-based technology for human nervous system analysis.
  • Establishment of SenceTech – the company responsible for implementing Planexta Inc. technologies in the United States and other developed countries.

September 2017

  • The Cryptofund’s development strategy is finalized.
  • Publication of a fundamental scientific paper on aging predictor analysis and the dynamic estimation of biological age.
  • Development of a unique new algorithm for ECG annotation.
  • Establishment of Precise Cardiology Limited, which provides automated ECG interpretation services to healthcare systems.

October 2017

  • The Cryptofund’s portfolio is created.
  • The medical version of SenceBand is named among the top 20 remote assistance projects of 2017 by HealthcareTech Outlook.
  • Pre-clinical trials of Pure Purr begin.
  • SenceTech is chosen as one of the three biotech companies at TechCrunch Disrupt (Berlin).
  • SenceTech is selected for the Web Summit PITCH.

November –
January 2017

The Fund conducts a Roadshow for the purpose of engaging investors and partners for the Cryptofund.

January 2018

Establishment and registration of the Cryptofund.

February 2018

Creation of the Cryptofund’s board of directors and investment strategy.

February –
August 2018

Preparation for the ITO and coordination with regulators for the purpose of issuing tokens.

March 2018

Establishment of the Cryptofund’s hedge-fund division for the purpose of liquidity management.

August 2018

Demonstration of successful technological and financial results by the Cryptofund’s portfolio companies.

September 2018

Launch of our ITO

October 2018

  • Portfolio companies begin investment using gathered funds.
  • Launch of the first stage of our A.R.K. infrastructure project, specifically – the initial laboratory construction phase.

November 2018
(constant/daily process)

payment of dividends to token owners.

November 2018

Launch of the final stage of the A.R.K. infrastructure project.

November 2018

Launch of the final stage of the A.R.K. infrastructure project.

January 2019

Launch of new technological projects within the Cryptofund.


Irene Brinker

Chicago, USA

CEO/Co-Founder - SenceTech, Inc (Vanhealthing portfolio company), CCO - Planexta, Inc. Startegic Commercialization Advisor - Vanhealthing. Irene Brinker is a 20+ year veteran sales and marketing leader known for out of the box concept and process creation resulting in high margin ROI for partners and investors. With a diverse background bridging consumer goods, high-value services, and financial investment/sales she brings a well-rounded perspective and trained eye to Vanhealthing.

Ivan Danishevsky

Kyiv, Ukraine

Chief Promotion Officer of VANHEALTHING fund, founder and CEO of media holding, which unites three innovative IT platforms (ESC, and in the fields of Big Data analytics, online payments and promotion of e-sports on the global scene. Has experience in managing large teams, as well as promoting media and high-tech projects.

Vanhealthing network token

Register to have an opportunity to buy token.

*This field is required
*This field is required